Ikarian Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Ikarian Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-600,000	Closed	-$5.27M	–	187
2021 Q3	$5.27M	Buy	+600,000	New	+$5.51M	0.37%	63

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Ikarian Capital's ALDX Position: Q3 2022 in Review

Ikarian Capital sold out of Aldeyra Therapeutics (ALDX) in Q3 2022, closing a stake of 375,000 shares — an estimated $1.5M sold.

Ikarian Capital first reported a position in ALDX in Q1 2022 and held it in 2 quarters. The position peaked at $1.67M in Q1 2022. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

Ikarian Capital reported no remaining Aldeyra Therapeutics position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 375,000 Aldeyra Therapeutics shares in Q3 2022, an estimated $1.5M.
Ikarian Capital first reported a position in Aldeyra Therapeutics in Q1 2022 and held it in 2 quarters.
Ikarian Capital's Aldeyra Therapeutics position peaked at $1.67M in Q1 2022.
89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.